Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week

Motley Fool2021-08-06

What happened Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

110

Report

Comment（11）

zachfire
·2021-08-08
I'm holding many pharma stocks..
Reply
Like
Report
Fold Replies
- zachfire:
  ...
  2021-08-08
  Reply
  Report
Tze
·2021-08-08
[強]
Reply
1
Report
SPHSIAO
·2021-08-07
Good read!
Reply
3
Report
ArigatoMoney
·2021-08-06
Now dropping… ??‍♀️
Reply
2
Report
woonws
·2021-08-06
Good for them... but not so much for other vaccine makers like AstraZeneca and J&J
Reply
3
Report
limcainen
·2021-08-06
Like and comment
Reply
6
Report
javiery
·2021-08-06
Gd read
Reply
4
Report
Jimmyboy
·2021-08-06
Please like and comment.
Reply
6
Report
Fold Replies
- Izafs:
  Ok
  2021-08-06
  Reply
  Report
Jasmine1205
·2021-08-06
Tsk..expensive vaccines and all need booster shots
Reply
5
Report
Fold Replies
- Jwong:
  Yah, they should donate vaccines to countries that can't afford them.
  2021-08-06
  Reply
  Report
Siak
·2021-08-06
Why?
Reply
4
Report
Likeabull
·2021-08-06
Good
Reply
4
Report
Fold Replies
- Likeabull:
  [Smile]
  2021-08-06
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2157646054?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-06 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2157646054","market":"us","top_or_hot":-1,"title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","media":"Motley Fool","content":"<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","article_id":"2157646054","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","pubTimestamp":1628255580,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Each vaccine stock had its own separate catalyst.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","DVAX":"德纳维制药"},"translate_title":"为什么COVID疫苗库存本周飙升莫德纳、生物技术公司、诺瓦瓦克斯医药和德纳维制药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9,"DVAX":0.9,"MRNA":0.9,"NVAX":0.9},"content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","kind":"highlight","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":891730040,"gmtCreate":1628425245580,"gmtModify":1703506126415,"author":{"id":"4088381730143720","authorId":"4088381730143720","name":"zachfire","avatar":"https://static.tigerbbs.com/cc1bf4715acf10cab7f9f9a0a63d66bf","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4088381730143720","authorIdStr":"4088381730143720"},"htmlText":"I'm holding many pharma stocks..","listText":"I'm holding many pharma stocks..","text":"I'm holding many pharma stocks..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/891730040","repostId":2157646054,"repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5463216,"gmtCreate":1628425288897,"gmtModify":1663232088529,"authorId":4088381730143720,"author":{"id":4088381730143720,"idStr":"4088381730143720","authorId":4088381730143720,"name":"zachfire","avatar":"https://static.tigerbbs.com/cc1bf4715acf10cab7f9f9a0a63d66bf","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":891730040,"type":1,"supId":0,"prevId":0,"content":"...","text":"...","html":"..."}],"langContent":"EN"},{"id":891542767,"gmtCreate":1628404067859,"gmtModify":1703505940789,"author":{"id":"3564633224342511","authorId":"3564633224342511","name":"Tze","avatar":"https://static.itradeup.com/news/0e60299fafdb24204f8c9bc3f137aac5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3564633224342511","authorIdStr":"3564633224342511"},"htmlText":"[強]&nbsp;","listText":"[強]&nbsp;","text":"[強]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/891542767","repostId":2157646054,"repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":893413172,"gmtCreate":1628295017096,"gmtModify":1703504585024,"author":{"id":"3581803366129219","authorId":"3581803366129219","name":"SPHSIAO","avatar":"https://static.tigerbbs.com/24c703622a1c3326d6a04c543fa7068d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581803366129219","authorIdStr":"3581803366129219"},"htmlText":"Good read!","listText":"Good read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893413172","repostId":2157646054,"repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":893294936,"gmtCreate":1628262955825,"gmtModify":1703504276004,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"htmlText":"Now dropping… ??‍♀️","listText":"Now dropping… ??‍♀️","text":"Now dropping… ??‍♀️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893294936","repostId":2157646054,"repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":893691399,"gmtCreate":1628258378311,"gmtModify":1703504124976,"author":{"id":"3581999478634265","authorId":"3581999478634265","name":"woonws","avatar":"https://static.tigerbbs.com/f26ed1a10ee84ab97229aad191ef3133","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581999478634265","authorIdStr":"3581999478634265"},"htmlText":"Good for them... but not so much for other vaccine makers like AstraZeneca and J&amp;J","listText":"Good for them... but not so much for other vaccine makers like AstraZeneca and J&amp;J","text":"Good for them... but not so much for other vaccine makers like AstraZeneca and J&J","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893691399","repostId":2157646054,"repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":893877915,"gmtCreate":1628257743337,"gmtModify":1703504107330,"author":{"id":"3581732292369755","authorId":"3581732292369755","name":"limcainen","avatar":"https://static.tigerbbs.com/348839af52a533d0af68ce7adb2e8f22","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581732292369755","authorIdStr":"3581732292369755"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893877915","repostId":2157646054,"repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":893844208,"gmtCreate":1628257371104,"gmtModify":1703504093289,"author":{"id":"3578269878229068","authorId":"3578269878229068","name":"javiery","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578269878229068","authorIdStr":"3578269878229068"},"htmlText":"Gd read&nbsp;","listText":"Gd read&nbsp;","text":"Gd read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893844208","repostId":2157646054,"repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":893843900,"gmtCreate":1628257135300,"gmtModify":1703504083027,"author":{"id":"3582072891665879","authorId":"3582072891665879","name":"Jimmyboy","avatar":"https://static.tigerbbs.com/cb9d5d497bceb3edaca216e9eeab3c22","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582072891665879","authorIdStr":"3582072891665879"},"htmlText":"Please like and comment.","listText":"Please like and comment.","text":"Please like and comment.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/893843900","repostId":2157646054,"repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5447615,"gmtCreate":1628257440959,"gmtModify":1663232020533,"authorId":3581936437092568,"author":{"id":3581936437092568,"idStr":"3581936437092568","authorId":3581936437092568,"name":"Izafs","avatar":"https://static.tigerbbs.com/8b90fcb3083cfc628794013e9d79b161","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":893843900,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":893827858,"gmtCreate":1628256447974,"gmtModify":1703504064109,"author":{"id":"3575175630342613","authorId":"3575175630342613","name":"Jasmine1205","avatar":"https://static.tigerbbs.com/4d0aaff576d8e7d6bd8a01ed04dc6434","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575175630342613","authorIdStr":"3575175630342613"},"htmlText":"Tsk..expensive vaccines and all need&nbsp;booster shots","listText":"Tsk..expensive vaccines and all need&nbsp;booster shots","text":"Tsk..expensive vaccines and all need booster shots","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/893827858","repostId":2157646054,"repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5447754,"gmtCreate":1628257997443,"gmtModify":1663232020931,"authorId":3584225860430865,"author":{"id":3584225860430865,"idStr":"3584225860430865","authorId":3584225860430865,"name":"Jwong","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":893827858,"type":1,"supId":0,"prevId":0,"content":"Yah, they should donate vaccines to countries that can't afford them.","text":"Yah, they should donate vaccines to countries that can't afford them.","html":"Yah, they should donate vaccines to countries that can't afford them."}],"langContent":"EN"},{"id":893821403,"gmtCreate":1628256077002,"gmtModify":1703504055981,"author":{"id":"3586817050833129","authorId":"3586817050833129","name":"Siak","avatar":"https://static.tigerbbs.com/ed2639a3eeb56c6706ffb23a3d0059fd","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3586817050833129","authorIdStr":"3586817050833129"},"htmlText":"Why?","listText":"Why?","text":"Why?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893821403","repostId":2157646054,"repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":893821582,"gmtCreate":1628256075446,"gmtModify":1703504055651,"author":{"id":"4089109132462390","authorId":"4089109132462390","name":"Likeabull","avatar":"https://static.tigerbbs.com/cbea55e98757d0fd9e84090cea5652ab","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4089109132462390","authorIdStr":"4089109132462390"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/893821582","repostId":2157646054,"repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5447381,"gmtCreate":1628256088465,"gmtModify":1663232017025,"authorId":4089109132462390,"author":{"id":4089109132462390,"idStr":"4089109132462390","authorId":4089109132462390,"name":"Likeabull","avatar":"https://static.tigerbbs.com/cbea55e98757d0fd9e84090cea5652ab","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":893821582,"type":1,"supId":0,"prevId":0,"content":"[Smile]","text":"[Smile]","html":"[Smile]"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":110,"commentSize":11,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}